

Keywords: *Helicobacter pylori*; chronic atrophic gastritis; DNA methylation age; gastric cancer; epigenetic epidemiology

Associations of *Helicobacter pylori* infection and chronic atrophic gastritis with accelerated epigenetic ageing in older adults

Xu Gao¹, Yan Zhang¹ and Hermann Brenner^{*,1,2,3}

¹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; ²Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany and ³German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

Background: *Helicobacter pylori* (HP) infection and chronic atrophic gastritis (CAG) have shown strong associations with the development of gastric cancer. This study aimed to examine whether both risk factors are associated with accelerated epigenetic ageing, as determined by the 'DNA methylation age', in a population-based study of older adults ($n = 1477$).

Methods: Serological measurements of HP antibodies and pepsinogen I and II for CAG definition were obtained by ELISA kits. Whole blood DNA methylation profiles were measured by Illumina Human Methylation450K Beadchip. DNA methylation ages were calculated by two algorithms proposed by Horvath and Hannum *et al.*

Results: After adjusting for potential covariates in linear regression models, we found that HP infection, infection with virulent HP strains (CagA+) and severe CAG were significantly associated with an increase in DNA methylation age by ~0.4, 0.6 and 1 year (all P -values < 0.05), respectively.

Conclusions: Our study indicates that both CagA+ HP infection and CAG go along with accelerated epigenetic ageing.

Gastric cancer is the third leading cause of cancer mortality globally (Ferlay *et al.*, 2015). *Helicobacter pylori* (HP) is related aetiologically to gastric cancer by playing a key role in the development of gastric carcinogenesis (Graham, 2015). HP infection also shows a causal relationship with chronic atrophic gastritis (CAG), a chronic, strongly age-related condition, which is a critical precursor lesion of gastric cancer (Weck and Brenner, 2008) and related to other chronic, age-related health outcomes, such as vitamin B₁₂ deficiency and cardiovascular disease (CVD) (Lewerin *et al.*, 2008; Franceschi *et al.*, 2009). Previous studies have shown that HP infection is closely related to DNA methylation changes in gastric mucosa and whole blood samples (Maekita *et al.*, 2006; Zhang *et al.*, 2016). One of the conceivable causes is that the oxidative stress induced by HP infection contributes to the

accelerated senescence of cells and ageing (Naito and Yoshikawa, 2002; Pandey and Rizvi, 2010). Moreover, based on the age-related alterations of DNA methylation, researchers have established the concept of DNA methylation age (Hannum *et al.*, 2013; Horvath, 2013), and have employed the discrepancy between DNA methylation age and chronological age (termed 'age acceleration' (AA)) as an informative biomarker of ageing and ageing-related health outcomes. Given the associations of HP infection with ageing and DNA methylation alterations, it would appear plausible that HP infection might have an impact on the disproportional ageing reflected by DNA methylation age. To investigate this hypothesis, we explored the associations of both HP infection and CAG with AA in a large population-based study of older adults (ESTHER) in Germany.

*Correspondence: Dr H Brenner; E-mail: h.brenner@dkfz-heidelberg.de

Received 31 May 2017; revised 3 August 2017; accepted 18 August 2017; published online 12 September 2017

© 2017 Cancer Research UK. All rights reserved 0007–0920/17

MATERIALS AND METHODS

The methods for this study are described in detail in Supplementary Material. Briefly, we selected 1509 older adults (aged 50–75 years) enrolled in the ESTHER study between July 2000 and March 2001 and collected their socio-demographic characteristics, lifestyle factors and health status by standardised questionnaires (Supplementary Figure 1) (Gao *et al*, 2016a). Participants were categorised into three groups according to the serostatus of immunoglobulin G (IgG) antibodies and antibodies specific to the cytotoxin-associated gene A (CagA): infected by less virulent strains (IgG+/CagA-), infected by virulent strains (IgG+/CagA+) and non-infected (IgG-/CagA-) (Chen *et al*, 2016). We excluded 32 participants with IgG-/CagA+ HP, which often reflects past infection. Serum concentrations of pepsinogen (PG) I and II were measured as biomarkers of CAG, and we used the following commonly employed serological classification to define CAG: PG I < 70 ng ml⁻¹ and PG I/II ratio < 3.0. Blood DNA methylation was quantified by Illumina 450K chip and the DNA methylation age of each participant was calculated by the algorithms of Horvath and Hannum *et al* (Hannum *et al*, 2013; Horvath, 2013). AAs were determined as the residuals calculated by the linear regression models of both forms of epigenetic age on chronological age (Gao *et al*, 2016b).

RESULTS

Table 1 summarises characteristics of the 1477 eligible participants. Average chronological age was ~62 years. Hannum *et al* methylation ages were higher than chronological age and age computed by Horvath's approach. Both forms of DNA methylation age and chronological age were highly correlated with each other (Supplementary Figure 2). The prevalence of any HP and CagA+ HP infection was 51.8% and 26.7%, respectively, and around 12% participants had CAG (mild or severe). HP infection status and serostatus were significantly associated with both AAs (Table 2; *P*-values < 0.05). Participants infected with virulent strains (CagA+) had the highest AAs, followed by those infected with less virulent strains (CagA-). Similarly, both AAs demonstrated positive correlations with the CAG status and severity of CAG, which was though statistically significant only for the AA based on the algorithm by Hannum *et al* (Table 2; *P*-values = 0.015/0.024).

We further examined the associations of AAs (outcomes) with HP infection status or CAG severity (independent variables) by three linear regression models, increasingly controlling for potential covariates. HP infection, infection with CagA+ strains and severe CAG were significantly associated with both AAs after adjustment for age, sex and the leucocyte distribution (Table 3; all *P*-values < 0.05). Although in the fully adjusted model, associations of the AA according to Horvath's algorithm with HP infection/severe CAG were slightly attenuated (*P*-values = 0.05), additional adjustment for other covariates did not alter the patterns in any relevant manner. However, CAG (yes/no) was only associated with the AA according to Hannum's algorithm, but not the AA according to Horvath's algorithm. This pattern remained essentially unchanged in the sensitivity analysis in which we adjusted for both HP infection status and the CAG status simultaneously (*P*-value of CAG for AA_{Horvath} = 0.118; *P*-value of CAG for AA_{Hannum} = 0.012). Overall, we observed that HP infection, infection of CagA+ strains and severe CAG were associated with the DNA methylation-defined AA. In the fully adjusted model, these risk factors were associated with an increase in DNA methylation age by ~0.4, 0.6 and 1 year, respectively.

Table 1. Population characteristics of ESTHER study^a

| Characteristic | |
|---|--------------|
| N | 1477 |
| Age (years) | 62.0 (6.5) |
| Methylation age 1 (Horvath, years) | 62.2 (7.3) |
| Methylation age 2 (Hannum, years) | 68.2 (7.1) |
| Gender (male) | 495 (50.6%) |
| HP serostatus | |
| IgG-/CagA- | 712 (48.2%) |
| IgG+/CagA- | 371 (25.1%) |
| IgG+/CagA+ | 394 (26.7%) |
| Severity of CAG ^b | |
| Non-atrophic | 1304 (88.3%) |
| Mild atrophic | 75 (5.1%) |
| Severe atrophic | 98 (6.6%) |
| Smoking status | |
| Current smoker | 276 (18.7%) |
| Former smoker | 499 (33.8%) |
| Never smoker | 702 (47.5%) |
| Body mass index ^c | |
| Underweight or normal weight (<25.0) | 399 (27.1%) |
| Overweight (25 to <30) | 685 (46.5%) |
| Obese (≥30.0) | 390 (26.5%) |
| Alcohol consumption ^d | |
| Abstainer | 471 (34.3%) |
| Low | 804 (58.5%) |
| Intermediate | 78 (5.7%) |
| High | 21 (1.5%) |
| Physical activity ^e | |
| Inactive | 294 (19.9%) |
| Low | 673 (45.6%) |
| Medium or high | 510 (34.5%) |
| Education ^f | |
| ≤9 years | 1071 (74.1%) |
| 10–11 years | 224 (15.5%) |
| ≥12 years | 150 (10.4%) |
| Prevalence of CVD ^g (yes) | 265 (17.9%) |
| Prevalence of diabetes ^h (yes) | 230 (15.7%) |
| Prevalence of cancer (yes) | 88 (6.0%) |
| Abbreviations: CAG = chronic atrophic gastritis; CVD = cardiovascular disease; HP = <i>Helicobacter pylori</i> . | |
| ^a Mean values (s.d.) for continuous variables and n (%) for categorical variables. | |
| ^b Categories defined as follows: non-atrophic (PG I ≥ 70 ng ml ⁻¹ and PG I/II ratio ≥ 3.0), mild atrophic (20 ng ml ⁻¹ ≤ PG I < 70 ng ml ⁻¹ and PG I/II ratio < 3.0), severe atrophic (PG I < 20 ng ml ⁻¹ and PG I/II ratio < 3.0). | |
| ^c Data missing for three participants. | |
| ^d Data missing for 103 participants, respectively. Categories defined as follows: abstainer, low (women: 0 to <20 g d ⁻¹ , men: 0 to <40 g d ⁻¹), intermediate (20 to <40 g d ⁻¹ and 40 to <60 g d ⁻¹ , respectively), high (≥40 g d ⁻¹ and ≥60 g d ⁻¹ , respectively). | |
| ^e Categories defined as follows: inactive (<1 h of physical activity per week), medium or high (≥2 h of vigorous or ≥2 h of light physical activity per week), low (other). | |
| ^f Data missing for 32 participants. | |
| ^g Data missing for 16 participants. | |
| ^h Data missing for one participant. | |

DISCUSSION

In summary, we found HP infection, in particular, infection with CagA+ HP strains, to be associated with accelerated ageing. The underlying mechanisms are not yet to be elaborated by further research. A plausible pathological mechanism might be the oxidative damage triggered by the reactive oxygen species that resulted from the inflammation induced by the HP infection (Farinati *et al*, 2008). The damage caused by oxidative stress has been commonly recognised as a contributor to the functional decline related to ageing (Hekimi *et al*, 2011) and has been found

Table 2. Distributions of age accelerations based on *Helicobacter pylori* (HP) infection and severity of chronic atrophic gastritis (CAG)

| Categories | N | Age acceleration (Horvath) | | Age acceleration (Hannum) | |
|------------------------------|------|------------------------------|----------------------|------------------------------|----------------------|
| | | Median (interquartile range) | P-value ^a | Median (interquartile range) | P-value ^a |
| HP infection (yes/no) | | | 0.004 | | 0.007 |
| No (IgG-) | 712 | -0.635 (-3.558 to 2.660) | | -0.424 (-3.282 to 2.432) | |
| Yes (IgG+) | 765 | 0.218 (-2.974 to 3.383) | | 0.185 (-2.528 to 3.019) | |
| HP serostatus | | | 0.006 | | 0.014 |
| IgG-/CagA- | 712 | -0.635 (-3.558 to 2.660) | | -0.424 (-3.282 to 2.432) | |
| IgG+/CagA- | 371 | -0.249 (-3.107 to 2.979) | | -0.089 (-2.541 to 2.784) | |
| IgG+/CagA+ | 394 | 0.756 (-2.894 to 3.557) | | 0.450 (-2.470 to 3.102) | |
| HP infection risk | | | 0.005 | | 0.014 |
| Low (CagA-) | 1083 | -0.454 (-3.346 to 2.758) | | -0.291 (-3.092 to 2.536) | |
| High (CagA+) | 394 | 0.756 (-2.894 to 3.557) | | 0.450 (-2.470 to 3.102) | |
| CAG (yes/no) | | | 0.078 | | 0.015 |
| No (non-atrophic) | 1304 | -0.321 (-3.316 to 2.951) | | -0.220 (-2.972 to 2.677) | |
| Yes (mild/severe atrophic) | 173 | 0.687 (-2.975 to 3.399) | | 0.614 (-2.576 to 3.600) | |
| Severity of CAG | | | 0.155 | | 0.024 |
| Non-atrophic | 1304 | -0.321 (-3.316 to 2.951) | | -0.220 (-2.972 to 2.677) | |
| Mild atrophic | 75 | 0.307 (-3.275 to 3.168) | | 0.151 (-3.058 to 3.243) | |
| Severe atrophic | 98 | 1.208 (-2.975 to 3.463) | | 0.897 (-2.230 to 3.927) | |

Abbreviations: CAG = chronic atrophic gastritis.

^aTested by Wilcoxon test (binomial variables) or Kruskal-Wallis test (variables with three categories).

Bold values indicate that this P-value is less than 0.05 and therefore is statistically significant.

Table 3. Associations of *Helicobacter pylori* (HP) infection and severity of chronic atrophic gastritis (CAG) with age acceleration

| Categories | N | Age acceleration (Horvath) | | | | | | Age acceleration (Hannum) | | | | | |
|------------------------------|------|----------------------------|--------------|----------------------|--------------|----------------------|--------------|---------------------------|--------------|----------------------|--------------|----------------------|--------------|
| | | Model 1 ^a | | Model 2 ^b | | Model 3 ^c | | Model 1 ^a | | Model 2 ^b | | Model 3 ^c | |
| | | Beta (s.d.) | P-value | Beta (s.d.) | P-value | Beta (s.d.) | P-value | Beta (s.d.) | P-value | Beta (s.d.) | P-value | Beta (s.d.) | P-value |
| HP infection (yes/no) | | | | | | | | | | | | | |
| No (IgG-) | 712 | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes (IgG+) | 765 | 0.613 (0.242) | 0.011 | 0.376 (0.254) | 0.049 | 0.366 (0.255) | 0.050 | 0.538 (0.209) | 0.010 | 0.432 (0.217) | 0.026 | 0.450 (0.218) | 0.039 |
| HP serostatus | | | | | | | | | | | | | |
| IgG-/CagA- | 712 | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| IgG+/CagA- | 371 | 0.411 (0.297) | 0.166 | 0.371 (0.312) | 0.906 | 0.063 (0.313) | 0.841 | 0.399 (0.256) | 0.119 | 0.290 (0.267) | 0.277 | 0.312 (0.269) | 0.246 |
| IgG+/CagA+ | 394 | 0.803 (0.290) | 0.006 | 0.697 (0.307) | 0.023 | 0.652 (0.307) | 0.034 | 0.668 (0.251) | 0.008 | 0.567 (0.267) | 0.031 | 0.581 (0.263) | 0.028 |
| HP infection risk | | | | | | | | | | | | | |
| Low (CagA-) | 1083 | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| High (CagA+) | 394 | 0.659 (0.271) | 0.015 | 0.684 (0.288) | 0.018 | 0.631 (0.288) | 0.029 | 0.528 (0.234) | 0.024 | 0.468 (0.245) | 0.042 | 0.475 (0.247) | 0.045 |
| CAG (yes/no) | | | | | | | | | | | | | |
| No (non-atrophic) | 1304 | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Yes (mild/severe atrophic) | 173 | 0.648 (0.373) | 0.083 | 0.586 (0.390) | 0.134 | 0.637 (0.391) | 0.103 | 0.847 (0.322) | 0.009 | 0.790 (0.332) | 0.018 | 0.876 (0.334) | 0.009 |
| Severity of CAG | | | | | | | | | | | | | |
| Non-atrophic | 1304 | Ref | | Ref | | Ref | | Ref | | Ref | | Ref | |
| Mild atrophic | 75 | 0.150 (0.547) | 0.784 | 0.123 (0.566) | 0.828 | 0.181 (0.569) | 0.750 | 0.522 (0.472) | 0.268 | 0.517 (0.482) | 0.284 | 0.637 (0.487) | 0.191 |
| Severe atrophic | 98 | 1.030 (0.483) | 0.033 | 1.003 (0.508) | 0.049 | 0.994 (0.508) | 0.050 | 1.095 (0.417) | 0.009 | 1.064 (0.433) | 0.014 | 1.063 (0.434) | 0.015 |

Abbreviation: CAG = chronic atrophic gastritis; s.d.=standard deviation.

^aAdjusted for age, sex and the leucocyte distribution (Houseman algorithm).

^bModel 1 plus smoking status, body mass index (BMI, kg m⁻², underweight (<18.5, <1% of the study population) or normal weight (18.5 to <25), overweight (25 to <30), obese (≥30)), alcohol consumption (abstainer, low (women: 0 to <20 g d⁻¹, men: 0 to <40 g d⁻¹), intermediate (20 to <40 g d⁻¹ and 40 to <60 g d⁻¹, respectively), high (≥40 g d⁻¹ and ≥60 g d⁻¹, respectively)), education levels (≤9 years, 10–11 years, ≥12 years) and physical activity (inactive (<1 h of physical activity per week), medium or high (≥2 h of vigorous or ≥2 h of light physical activity per week), low (other)).

^cModel 2 plus prevalence of CVD, diabetes and cancers.

Bold values indicate that this P-value is less than 0.05 and therefore is statistically significant.

to be associated with ageing-related DNA methylation changes in whole blood samples (Gao *et al*, 2017).

Although we controlled for a large number of potential confounders in multivariate analyses, a causal relationship cannot be derived from this cross-sectional epidemiological study. Nevertheless, a causal relationship appears to be plausible due to a variety of reasons. First, HP infection is typically acquired in early

childhood (Zhang *et al*, 2012), a period during which the foundation of age acceleration seems to be laid (Simpkin *et al*, 2016), and clearly precedes the pattern of age acceleration observed among older adults in our study, despite its cross-sectional design. Second, both HP infection and CAG have been associated with a number of age-related chronic diseases, including but not restricted to gastric cancer, such as CVD and extra-gastric diseases (e.g.,

colonic and pancreatic cancer; Franceschi *et al*, 2009; Chen *et al*, 2016). Further research should address the association between HP infection and DNA methylation age at various ages across the lifespan, ideally in a large cohort study in which temporal relationship between the occurrence of HP infection and AA could be established by repeated measurements of both factors. Another question of major scientific interest and potential major public health relevance might be to what extent AA associated with CagA + HP infection could be reversible after HP eradication.

ACKNOWLEDGEMENTS

The ESTHER study was supported in part by the Baden-Württemberg state Ministry of Science, Research and Arts (Stuttgart, Germany) and the German Federal Ministry of Education and Research (Berlin, Germany). The work of Xu Gao is supported by the grant from the China Scholarship Council (CSC). The authors gratefully acknowledge contributions of DKFZ Genomics and Proteomics Core Facility, especially Dr Melanie Bewerunge-Hudler and Dr Matthias Schick, in the processing of DNA samples and performing the laboratory work, Dr Jonathan Heiss for providing the estimation of leucocyte distribution and Ms. Chen Chen for the language assistance.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Chen XZ, Schöttker B, Castro FA, Chen H, Zhang Y, Holleczer B, Brenner H (2016) Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: a ten-year follow-up of the ESTHER cohort study. *Oncotarget* **7**(13): 17182–17193.
- Farinati F, Cardin R, Cassaro M, Bortolami M, Nitti D, Tieppo C, Zaninotto G, Rugge M (2008) Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. *Eur J Cancer Prev* **17**(3): 195–200.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* **136**(5): E359–E386.
- Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, Feroce F, Saulnier N, Conte M, Roccarina D, Lanza GA, Gasbarrini G, Gentiloni SN, Crea F (2009) CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. *Atherosclerosis* **202**(2): 535–542.
- Gao X, Gao X, Zhang Y, Breitling LP, Schottker B, Brenner H (2017) Associations of self-reported smoking, cotinine levels and epigenetic smoking indicators with oxidative stress among older adults: a population-based study. *Eur J Epidemiol* **32**(5): 443–456.
- Gao X, Mons U, Zhang Y, Breitling LP, Brenner H (2016a) DNA methylation changes in response to active smoking exposure are associated with leucocyte telomere length among older adults. *Eur J Epidemiol* **31**(12): 1231–1241.
- Gao X, Zhang Y, Breitling LP, Brenner H (2016b) Relationship of tobacco smoking and smoking-related DNA methylation with epigenetic age acceleration. *Oncotarget* **7**(30): 46878–46889.
- Graham DY (2015) Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. *Gastroenterology* **148**(4): 719–31.e3.
- Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sada S, Klotzle B, Bibikova M, Fan JB, Gao Y, Deconde R, Chen M, Rajapakse I, Friend S, Ideker T, Zhang K (2013) Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell* **49**(2): 359–367.
- Hekimi S, Lapointe J, Wen Y (2011) Taking a ‘good’ look at free radicals in the aging process. *Trends Cell Biol* **21**(10): 569–576.
- Horvath S (2013) DNA methylation age of human tissues and cell types. *Genome Biol* **14**(10): R115.
- Lewerin C, Jacobsson S, Lindstedt G, Nilsson-Ehle H (2008) Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy. *Scand J Gastroenterol* **43**(9): 1050–1056.
- Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arai K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. *Clin Cancer Res* **12**(3 Pt 1): 989–995.
- Naito Y, Yoshikawa T (2002) Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. *Free Radic Biol Med* **33**(3): 323–336.
- Pandey KB, Rizvi SI (2010) Markers of oxidative stress in erythrocytes and plasma during aging in humans. *Oxid Med Cell Longev* **3**(1): 2–12.
- Simpkin AJ, Hemani G, Suderman M, Gaunt TR, Lyttleton O, McArdle WL, Ring SM, Sharp GC, Tilling K, Horvath S, Kunze S, Peters A, Waldenberger M, Ward-Caviness C, Nohr EA, Sorensen TI, Relton CL, Smith GD (2016) Prenatal and early life influences on epigenetic age in children: a study of mother-offspring pairs from two cohort studies. *Hum Mol Genet* **25**(1): 191–201.
- Weck MN, Brenner H (2008) Association of Helicobacter pylori infection with chronic atrophic gastritis: Meta-analyses according to type of disease definition. *Int J Cancer* **123**(4): 874–881.
- Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H (2012) Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. *Am J Epidemiol* **175**(5): 441–450.
- Zhang Y, Zhang XR, Park JL, Kim JH, Zhang L, Ma JL, Liu WD, Deng DJ, You WC, Kim YS, Pan KF (2016) Genome-wide DNA methylation profiles altered by Helicobacter pylori in gastric mucosa and blood leucocyte DNA. *Oncotarget* **7**(24): 37132–37144.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)